Zdravotnictví 10 Únor 2026 - 23 Únor 2026

Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
···

Proč akcie SLS před trhem rostou: SELLAS Life Sciences znovu spouští odpočet fáze 3 studie REGAL

SELLAS Life Sciences rose 3.4% to $4.29 in premarket trading Monday after closing Friday at $4.15 on heavy volume. Traders are watching for the 80th event in the phase 3 REGAL trial for AML, with results expected by mid-March. Short interest stands at 41.33 million shares, or 24.4% of float. SELLAS reported $71.8 million in cash at year-end, plus $26.5 million from recent warrant exercises.
23 února, 2026
AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
···

Akcie AbbVie (ABBV): FDA schválila novou kombinaci Venclexta-Calquence pro CLL — na co si dát v pondělí pozor

U.S. regulators approved a new first-line treatment for chronic lymphocytic leukemia combining AbbVie’s Venclexta and AstraZeneca’s Calquence, citing improved progression-free survival over standard therapy. AbbVie shares closed up 0.21% at $224.81 Friday. Barclays initiated coverage with an “overweight” rating and $275 target. Investors await further market reaction when trading resumes Monday.
23 února, 2026
UnitedHealth stock holds near $290 as Medicare Advantage rates loom — what to watch next week
···

Akcie UnitedHealth se drží kolem 290 dolarů, blíží se sazby Medicare Advantage — co sledovat příští týden

UnitedHealth shares closed Friday at $290, up just 0.02%, after a volatile session. New federal data show Medicare Advantage enrollment growth is slowing, with about 35.5 million members in early February. Insurers including UnitedHealthcare and Aetna have cut benefits and exited some regions. CMS will close public comments on proposed 2027 payment changes on Feb. 25.
22 února, 2026
Takeda’s $1.7 billion AI drug discovery deal with Iambic: what’s inside the pact
···

Takedova dohoda o objevování léků pomocí AI s Iambic za 1,7 miliardy dolarů: co je obsahem paktu

Takeda signed a multi-year drug discovery partnership with private firm Iambic, with milestone payments potentially exceeding $1.7 billion plus royalties. The collaboration will focus on small-molecule programs targeting oncology, gastrointestinal, and inflammatory diseases. Takeda will access Iambic’s NeuralPLexer AI model to predict drug-target binding.
10 února, 2026